Clinical outcome of gemcitabine/S-1 combination therapy for advanced pancreatic cancer

Pancreas. 2008 Apr;36(3):327-8. doi: 10.1097/MPA.0b013e31815cc464.
No abstract available

MeSH terms

  • Antimetabolites, Antineoplastic / administration & dosage
  • Antimetabolites, Antineoplastic / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / adverse effects
  • Deoxycytidine / analogs & derivatives
  • Drug Combinations
  • Drug Therapy, Combination
  • Drug Tolerance
  • Gemcitabine
  • Humans
  • Oxonic Acid / administration & dosage
  • Oxonic Acid / adverse effects
  • Pancreatic Neoplasms / drug therapy*
  • Pancreatic Neoplasms / secondary
  • Retrospective Studies
  • Tegafur / administration & dosage
  • Tegafur / adverse effects
  • Treatment Outcome

Substances

  • Antimetabolites, Antineoplastic
  • Drug Combinations
  • Deoxycytidine
  • S 1 (combination)
  • Tegafur
  • Oxonic Acid
  • Gemcitabine